Gastrointestinal effects of aspirin

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 7, 2011, Pages 385-394

  Sostres, Carlos ^a   Lanas, Angel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ANTICOAGULANT AGENT; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MELATONIN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PHOSPHATIDYLCHOLINE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; TRYPTOPHAN;

ACUTE CORONARY SYNDROME; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; COLON CANCER; COLON POLYP; COLORECTAL ADENOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; DYSPEPSIA; ENTERIC COATED TABLET; ERADICATION THERAPY; EROSION; ESOPHAGITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL EROSION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL MUCOSAL DAMAGE; GASTROINTESTINAL PETECHIA; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; LOW DRUG DOSE; MUCOSAL DISEASE; NONHUMAN; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PETECHIA; POLYP; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STOMACH DISEASE; STOMACH EROSION; STOMACH LESION; STOMACH PROTECTION; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HUMANS; RISK FACTORS; STOMACH ULCER;

EID: 79960086239     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.97     Document Type: Review

References (116)

1. Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387-437 (2004) (Pubitemid 39096597)
2. Loll, P. J., Picot, D. & Garavoto, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 2, 637-643 (1995)
3. Oullet, M., Riendeau, D. & Percival, M. D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl Acad. Sci. USA 98, 14583-14588 (2001) (Pubitemid 33121435)
4. Kim, C. & Beckles, G. L. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am. J. Prev. Med. 27, 1-7 (2004) (Pubitemid 38813177)
5. Esmatjes, E., Castell, C., Franch, J., Puigoriol, E. & Hernandez, R. Acetylsalicylic acid consumption in patients with diabetes mellitus [Spanish]. Med. Clin. (Barc.) 122, 96-98 (2003)
6. Wallace, J. L. & Chin, B. C. Inflammatory mediators in gastrointestinal defense and injury. Proc. Soc. Exp. Biol. Med. 214, 192-203 (1997)
7. Silen, W. & Ito, S. Mechanisms for rapid re-epithelialization of the gastric mucosal surface. Annu. Rev. Physiol. 47, 217-229 (1985) (Pubitemid 15142379)
8. Konturek, S. J., Dembinski, A., Warzecha, Z., Brzozowski, T. & Gregory, H. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 94, 1300-1307 (1988)
9. Tarnawski, A., Szabo, I. L., Husain, S. S. & Soreghan, B. Regeneration of gastric mucosa during ulcer healing is triggered by growth factors and signal transduction pathways. J. Physiol. Paris 95, 337-344 (2001) (Pubitemid 33020258)
10. Ma, L., et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc. Natl Acad. Sci. USA 98, 6470-6475 (2001) (Pubitemid 32488261)
11. Reuter, B. K., Cirino, G. & Wallace, J. L. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci. 55, PL1-PL8 (1994) (Pubitemid 24185770)
12. Capone, M. L., et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468-1471 (2004) (Pubitemid 38420172)
13. Capone, M. L., et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 82, 85-94 (2007) (Pubitemid 44895440)
14. Tomisato, W., et al. Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. Biochem. Pharmacol. 67, 575-585 (2004) (Pubitemid 38232897)
15. Hingson, D. J. & Ito, S. Effect of aspirin and related compounds on the fine structure of mouse gastric mucosa. Gastroenterology 61, 156-177 (1971)
16. Geall, M. G., Phillips, S. F. & Summerskill, W. H. Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acid. Gastroenterology 58, 437-443 (1970)
17. Baskin, W. N., Ivey, K. J., Krause, W. J., Jeffrey, G. E. & Gemmell, R. T. Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference. Ann. Intern. Med. 85, 299-303 (1976)
18. OLaughlin, J. C., Hoftiezer, J. W. & Ivey, K. J. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand. J. Gastroenterol. Suppl. 67, 211-214 (1981) (Pubitemid 11123094)
19. Derry, S. & Loke, Y. K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321, 1183-1187 (2000)
20. Sorensen, H. T., et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am. J. Gastroenterol. 95, 2218-2224 (2000)
21. Kelly, J. P., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348, 1413-1416 (1996) (Pubitemid 26395236)
22. Chowdhury, A., et al. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J. Gastroenterol. 20, 227-229 (2001) (Pubitemid 33104618)
23. Garcia Rodriguez, L. A., Hernandez-Diaz, S. & de Abajo, F. J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br. J. Clin. Pharmacol. 52, 563-571 (2001)
24. Lichtenberger, L. M. Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol. 61, 631-637 (2001) (Pubitemid 32239415)
25. Rainsford, K. D. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am. J. Med. 107, 27S-35S (1999)
26. Bjarnason, I., Scarpignato, C., Takeuchi, K. & Rainsford, K. D. Determinants of the short term gastric damage caused by NSAIDs in man. Aliment. Pharmacol. Ther. 26, 95-106 (2007) (Pubitemid 46889838)
27. Darling, R. L., et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 127, 94-104 (2004) (Pubitemid 38962278)
28. Lichtenberger, L. M., Richards, J. E. & Hills, B. A. Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa. Gastroenterology 88, 308-314 (1985) (Pubitemid 15224610)
29. Oh, K. W., Qian, T., Brenner, D. A. & Lemasters, J. J. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol. Sci. 73, 44-52 (2003) (Pubitemid 36609084)
30. Kamada, G., et al. Evaluation of gastric mucosal blood flow using contrast enhanced ultrasonography during low dose aspirin therapy and during NSAID and low dose aspirin combined therapy [abstract M1114]. Gastroenterology 134 (Suppl. 1), A-341 (2008)
31. Odashima, M., et al. Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phosphodiesterase in rats. Dig. Dis. Sci. 52, 1355-1359 (2007) (Pubitemid 46626186)
32. Mahmud, T., Scott, D. L. & Bjarnason, I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann. Rheum. Dis. 55, 211-213 (1996) (Pubitemid 26122246)
33. Konturek, P. C., Kania, J., Hahn, E. G. & Konturek, J. W. Ascorbic acid attenuates aspirin induced gastric damage: role of inducible nitric oxide synthase. J. Physiol. Pharmacol. 57 (Suppl. 5), 125-136 (2006) (Pubitemid 46569789)
34. Davies, N. M. & Wallace, J. L. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J. Gastroenterol. 32, 127-133 (1997) (Pubitemid 27075895)
35. Smecuol, E., et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin. Gastroenterol. Hepatol. 7, 524-529 (2009)
36. Goldstein, J. L., et al. Video capsule endoscopy to prospectively assesses small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin. Gastroenterol. Hepatol. 3, 133-141 (2005) (Pubitemid 40220308)
37. Massó González, E. L., Patrignani, P., Tacconelli, S. & Rodríguez, L. A. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 62, 1592-1601 (2010)
38. Tanaka, A., Araki, H., Komoike, Y., Hase, S. & Takeuchi, K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J. Physiol. Paris 95, 21-27 (2001) (Pubitemid 33020214)
39. Campbell, C. L., Smyth, S., Montalescot, G. & Steinhubl, S. R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297, 2018-2024 (2007) (Pubitemid 46740354)
40. Cohen, M. M. & MacDonald, W. C. Mechanism of aspirin injury to human gastroduodenal mucosa. Prostaglandins Leukot. Med. 9, 241-255 (1982) (Pubitemid 12042903)
41. Hogan, D. L., Ainsworth, M. A. & Isenberg, J. I. Review article: gastroduodenal bicarbonate secretion. Aliment. Pharmacol. Ther. 8, 475-488 (1994) (Pubitemid 24324484)
42. Johansson, C., Aly, A., Befrits, R., Smedfors, B. & Uribe, A. Protection of the gastroduodenal mucosa by prostaglandins. Scand. J. Gastroenterol. Suppl. 110, 41-48 (1985) (Pubitemid 15002232)
43. Cole, A. T., et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction? Aliment. Pharmacol. Ther. 13, 187-193 (1999) (Pubitemid 29090014)
44. Arai, I., Hirose, H., Muramatsu, M., Okuyama, S. & Aihara, H. Possible involvement of non-steroidal anti-inflammatory drugs in vagal-mediated gastric acid secretion in rats. Jpn J. Pharmacol. 37, 91-99 (1985) (Pubitemid 15199849)
45. Jaramillo, E., et al. The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells. Scand. J. Gastroenterol. 24, 1231-1237 (1989) (Pubitemid 20015802)
46. Leivonen, M., Sipponen, P. & Kivilaakso, E. Gastric changes in coronary-operated patients with low-dose aspirin. Scand. J. Gastroenterol. 27, 912-916 (1992)
47. Niv, Y., et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig. Dis. Sci. 50, 78-80 (2005) (Pubitemid 40379143)
48. Yeomans, N. D., et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment. Pharmacol. Ther. 22, 795-801 (2005) (Pubitemid 41564359)
49. Sopena, F. & Lanas, A. How to advise aspirin use in patients who need NSAIDs. Curr. Pharm. Des. 13, 2248-2260 (2007) (Pubitemid 47317033)
50. Capone, M. L., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol. 45, 1295-1301 (2005) (Pubitemid 40523153)
51. Patrono, C., Garcia Rodriguez, L. A., Landolfi, R. & Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373-2383 (2005) (Pubitemid 41713749)
52. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002)
53. Maulaz, A. B., Bezerra, D. C. & Michel, P. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch. Neurol. 62, 1217-1220 (2005) (Pubitemid 41168347)
54. Berger, J. S., Brown, D. L. & Becker, R. C. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am. J. Med. 121, 43-49 (2008)
55. Dalen, J. E. Aspirin to prevent heart attack and stroke: whats the right dose? Am. J. Med. 119, 198-202 (2006) (Pubitemid 43255057)
56. Lanas, A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin. Drug Saf. 10, 45-54 (2011)
57. Baigent, C., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Antithrombotic Trialists (ATT) Collaboration. Lancet 373, 1849-1860 (2009)
58. Ridker, P. M., MacFadyen, J., Libby, P. & Glynn, R. J. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol. 106, 204-209 (2010)
59. Yeomans, N., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am. J. Gastroenterol. 103, 2465-2473 (2008)
60. Scheiman, J. M., et al. Prevention of low-dose acetylsalicylic acidassociated gastric/duodenal ulcers with esomeprazole 20 mg and 40 mg once daily in patients at increased risk of ulcer development: a randomized controlled trial (OBERON). Gastroenterology 136, A-70 (2009)
61. Lanas, A. Nonsteroidal anti-inflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer. Am. J. Med. Sci. 338, 96-106 (2009)
62. Hayden, M., Pignone, M., Phillips, C. & Mulrow, C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 136, 161-172 (2002) (Pubitemid 34073943)
63. McQuaid, K. R. & Laine, L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119, 624-638 (2006) (Pubitemid 44128438)
64. Juul-Moller, S., et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 340, 1421-1425 (1992)
65. The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338, 1345-1349 (1991)
66. Lanas, A., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am. J. Gastroenterol. 100, 1685-1693 (2005) (Pubitemid 41648418)
67. Fortun, P. J. & Hawkey, C. J. Nonsteroidal antiinfl ammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 21, 169-175 (2005) (Pubitemid 40316198)
68. Bjarnason, I., Williams, P., Smethurst, P., Peters, T. J. & Levi, A. J. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 27, 1292-1299 (1986)
69. Bjarnason, I., et al. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 102, 1546-1550 (1992)
70. Moore, R. A., Derry, S. & McQuay, H. J. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res. Ther. 10, R7 (2008)
71. Lanas, A. & Scheiman, J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin. 23, 163-173 (2007) (Pubitemid 46201599)
72. Hernandez-Diaz, S. & Garcia Rodriguez, L. A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 4, 22 (2006)
73. Bhatt, D. L., et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52, 1502-1517 (2008)
74. Harrington, R. A., et al. American College of Chest Physicians. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (Suppl. 6), 670S-707S (2008) (Pubitemid 351892975)
75. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339 (1996)
76. Ibáñez, L., et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment. Pharmacol. Ther. 23, 235-242 (2006) (Pubitemid 43382032)
77. Lanas, A., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 55, 1731-1738 (2006) (Pubitemid 44893570)
78. Chan, F. K., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352, 238-244 (2005) (Pubitemid 40110812)
79. Lanas, A., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with NSAIDs and anti-platelet agents. Am. J. Gastroenterol. 102, 507-515 (2007) (Pubitemid 46328156)
80. Lanas, A., et al. Nitrovasodilators, low dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 343, 834-839 (2000)
81. Taha, A. S., McCloskey, C., Prasad, R. & Bezlyak, V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374, 119-125 (2009)
82. Nema, H. & Kato, M. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. World J. Gastroenterol. 16, 5342-5346 (2010)
83. Ng, F. H., et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138, 82-88 (2010)
84. Ho, P. M., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J. Am. Med. Assoc. 301, 937-944 (2009)
85. Laine, L. & Hennekens, C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol. 105, 34-41 (2010)
86. Juurlink, D. N., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180, 713-718 (2009)
87. Gilard, M., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256-260 (2008)
88. Sibbing, D., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101, 714-719 (2009)
89. Small, D. S., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 48, 475-484 (2008) (Pubitemid 351389118)
90. Bhatt, D. L., et al. The COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363, 1909-1917(2010)
91. FDA Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm (2009)
92. EMEA Public statement on possible interaction between clopidogrel and proton pump inhibitors [online], http://www.ema.europa.eu/docs/en-GB/document- library/Public-statement/2009/11/WC500014409.pdf (2009)
93. Lanas, A., et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low dose aspirin. Aliment. Pharmacol. Ther. 16, 779-786 (2002) (Pubitemid 34407526)
94. Chan, F. K., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967-973 (2001) (Pubitemid 32240315)
95. Lai, K. C., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346, 2033-2038 (2002) (Pubitemid 34680594)
96. Fletcher, E. H., et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment. Pharmacol. Ther. 32, 831-839 (2010)
97. Lanas, A. & Hunt, R. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann. Med. 38, 415-428 (2006) (Pubitemid 44484879)
98. Gao, R. & Li, X. Risk assessment and aspirin use in Asian and Western populations. Vasc. Health Risk Manag. 6, 943-956 (2010)
99. Lanas, A., et al. First Spanish consensus on peptic ulcer bleeding management. Consenso sobre Hemorragia Digestiva por lcera Péptica [Spanish]. Med. Clin. (Barc.) 135, 608-616 (2010)
100. Sung, J. Y., et al. Continuation of low dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann. Intern. Med. 152, 1-9 (2010)
101. Brzozowska, I., et al. Role of prostaglandins, nitric oxide, sensory nerves and gastrin in acceleration of ulcer healing by melatonin and its precursor, L-tryptophan. J. Pineal Res. 32, 149-162 (2002) (Pubitemid 34309881)
102. Konturek, S. J., Konturek, P. C. & Brzozowski, T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J. Physiol. Pharmacol. 57 (Suppl. 5), 51-66 (2006) (Pubitemid 46569784)
103. Konturek, P. C., et al. Role of melatonin in mucosal gastroprotection against aspirin-induced gastric lesions in humans. J. Pineal Res. 48, 318-323 (2010)
104. Pilotto, A., Franceschi, M., Maggi, S., Addante, F. & Sancarlo, D. Optimal management of peptic ulcer disease in the elderly. Drugs Aging 27, 545-558 (2010)
105. Chan, A. T., et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134, 21-28 (2008) (Pubitemid 350309311)
106. Rothwell, P. M., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741-1750 (2010)
107. Cole, B. F., et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl Cancer Inst. 101, 256-266 (2009)
108. Meyer, B. J. Antithrombotic drugs: insights from cardiology. Cerebrovasc. Dis. 8, 19-27 (1998) (Pubitemid 28491087)
109. Patrono, C. in Platelets in thrombotic and non thrombotic disorders: pathophysiology, pharmacology and therapeutics 919-928 (Cambridge University Press, 2002)
110. Hankey, G. J. & Eikelboom, J. W. Aspirin resistance. Lancet 367, 606-617 (2006) (Pubitemid 43250663)
111. Wallace, J. L. & Ma, L. Inflammatory mediators in gastrointestinal defence and injury. Exp. Biol. Med. (Maywood) 226, 1003-1015 (2001)
112. Wallace, J. L. & Miller, M. J. Nitric oxide in mucosal defence: A little goes a long way. Gastroenterology 119, 512-520 (2000) (Pubitemid 30622002)
113. Fiorucci, S., et al. Gastrointestinal safety of NO-aspirin (NCX 4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124, 600-607 (2003) (Pubitemid 36268478)
114. Goddard, P. J. & Lichtenberger, L. M. In vitro recovery of canine gastric mucosal surface hydrophobicity and potential difference after aspirin damage. Dig. Dis. Sci. 40, 1357-1359 (1995)
115. Cryer, B., et al. Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am. J. Gastroenterol. 106, 272-277 (2011)
116. Giustarini, D., Del Soldato, P., Sparatore, A. & Rossi, R. Modulation of thiol homeostasis induced by H2S-releasing aspirin. Free Radic. Biol. Med. 48, 1263-1272 (2010)